ARTICLE | Clinical News
AKB-9778: Phase I data
March 26, 2012 7:00 AM UTC
A U.S. Phase I trial in 48 healthy volunteers showed that single ascending-doses of AKB-9778 were well tolerated. Aerpio plans to start a Phase Ib/IIa trial of AKB-9778 to treat DME in 2Q12. In Januar...